利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.024 秒)

    TRICYCLIC 6-ALKYLIDENE-PENEMS AS CLASS-D ß-LACTAMASES INHIBITORS
    4.
    发明公开
    TRICYCLIC 6-ALKYLIDENE-PENEMS AS CLASS-D ß-LACTAMASES INHIBITORS 审中-公开
    三环6亚烷基青霉烯为Class-D - - 内酰胺酶抑制剂

    公开(公告)号：EP1885358A2

    公开(公告)日：2008-02-13

    申请号：EP06824758.4

    申请日：2006-05-25

    申请人： Wyeth

    发明人： MANSOUR, Tarek Suhayl ,  VENKATESAN, Aranapakam Mudumbai

    IPC分类号： A61K31/424 ,  A61K31/43 ,  A61P31/04

    CPC分类号： A61K31/424 ,  A61K31/43

    摘要： This invention relates to certain tricyclic 6-alkylidene penems which act as a inhibitor of class-D enzymes. β-Lactamases hydrolyze β-lactam antibiotics, and as such serve as the primary cause of bacterial resistance. The compounds of the present invention when combined with β-lactam antibiotics will provide an effective treatment against life threatening bacterial infections. In accordance with the present invention there are provided compounds of formula I which are useful for treatment of bacterial infections having class-D enzymes associated therewith (Formula I): wherein: One of A and B denotes hydrogen and the other an optionally substituted fused tricyclic heteroaryl group; and X is S or O.

    BICYCLIC 6-ALKYLIDENE-PENEMS AS CLASS-D BETA-LACTAMASES INHIBITORS
    5.
    发明公开
    BICYCLIC 6-ALKYLIDENE-PENEMS AS CLASS-D BETA-LACTAMASES INHIBITORS 审中-公开
    BICYCLISCHE 6- ALKYLIDEN-PENEME KLASSE ALS-D-β-内酰胺酶，缝边

    公开(公告)号：EP1885357A1

    公开(公告)日：2008-02-13

    申请号：EP06771575.5

    申请日：2006-05-26

    申请人： Wyeth

    发明人： MANSOUR, Tarek Suhayl ,  VENKATESAN, Aranapakam Mudumbai

    IPC分类号： A61K31/424 ,  A61K31/429 ,  A61K31/43 ,  A61P31/04

    CPC分类号： A61K31/43 ,  A61K31/424 ,  A61K31/429 ,  A61K2300/00

    摘要： ABSTRACT This invention relates to certain bicyclic 6-alkylidene penems which act as a inhibitor of class-D enzymes. β-Lactamases hydrolyze β-lactam antibiotics, and as such serve as the primary cause of bacterial resistance. The compounds of the present invention when combined with β-lactam antibiotics will provide an effective treatment against life threatening bacterial infections. In accordance with the present invention there are provided compounds of general formula I or a pharmaceutically acceptable salt or in vivo hydrolyzable ester R5 thereof: Formula (I) wherein: One of A and B denotes hydrogen and the other an optionally substituted fused bicyclic heteroaryl group; and X=O or S.